Additional Information
has the experience
and resources to
handle complex claims involving prescription medication.
Bextra
If you or someone you love has suffered serious harm as a result of taking Vioxx, Celebrex or Bextra, you may be eligible to seek compensation, including medical bills, lost earning capacity, pain and suffering, and more.* Contact the defective drug lawyers at the Simmons firm today These experienced lawyers will evaluate your case, answer your questions, and help you understand your legal rights, including the filing of your pharmaceutical litigation.
Initial reports treated drugs like Bextra as miracle drugs, as they seemed to work better than traditional nonsterodial anti-inflammatories (NSADs) like ibuprofen or aspirin. Even better, they provided pain relief without the serious problems from stomach ulcers, including bleeding, that was associated with long-term use.
Unfortunately, Cox-2 Inhibitors were later cited in several studies as significantly increasing the chance of heart attack or stroke in people who have taken the drugs. As a result on April 7, 2005, the FDA withdrew Bextra from the market.
See the Bextra timeline of events.
What is Bextra?
In 2001 Bextra joined the then-growing list of Cox-2 Inhibitors on the billion-dollar pain reliever market. Cox-2 Inhibitors are used to treat osteoarthritis, acute pain and painful menstrual cycles.
Other popular Cox-2 Inhibitors are Vioxx and Celebrex. For more information see:
FDA Warnings
The FDA removed Bextra from the market due to its dangerous side effects.
Contact the Simmons Firm
The Simmons firm is experienced in handling pharmaceutical litigation.* However, our practice also handles litigation for: mesothelioma, commercial property, intellectual property, and defective medical devices.
For defective drug lawyers or lawyers for other legal matters, contact the Simmons firm.
* Please note that recovery results vary per client. The recovery amounts in each case reflect the specific facts of that case. Further, recovery amounts in past cases are not a guarantee of future results.
Resources for Clients
- FDA MedWatch for Bextra
- United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research
- New England Journal of Medicine
- American College of Rheumatology
- The Arthritis Foundation
- The National Databank for Rheumatoid Diseases
- American Heart Institute
- American Stroke Association